The POLARIS data for ETX101 are directionally compelling and mechanistically novel, but the evidence tier — single-arm Phase 1/2, maximum n=9 at any dose level, Month 12 subsets of n=3 and n=5 — cannot carry the weight the headline figures invite. Median monthly countable seizure frequency reductions of approximately 76% (DL3, n=5) and approximately 60% (DL4, n=9) through 52 weeks, deepening to 79% and 89% respectively at Month 12, are numerically substantial in a disease where seizure control is the primary unmet need. The cognitive and developmental trajectory signal — progressive gains approaching neurotypical children in those treated before two years of age — is the most differentiated element of this dataset and is absent from the evidence bases of every approved Dravet syndrome pharmacotherapy (fenfluramine, cannabidiol, stiripentol), all of which are chronic adjunctive small-molecule agents mechanistically distinct from ETX101's AAV9-based SCN1A gene regulation approach. No precedent in the available evidence clears the mechanistic-fit bar: no AAV9-based SCN1A gene regulation therapy has been approved or assessed by any HTA body. The fenfluramine PBAC recommendation (2024) and G-BA assessment, and the cannabidiol CADTH and G-BA decisions, confirm that payers accept seizure frequency reduction as a meaningful endpoint and recognize high unmet need in Dravet syndrome — but all rested on Phase 3 RCT data with placebo comparators, a standard ETX101 has not yet approached. [1][2] A critical unresolved confound: the press release does not specify whether POLARIS participants were on concomitant antiepileptic drugs, which is standard of care in this population; without a control arm, the contribution of background therapy to observed reductions cannot be isolated. The sharpest risk is that the Month 12 efficacy figures — the most favorable in the dataset — rest on three and five patients respectively, making them statistically uninterpretable as standalone evidence.
POLARIS is a single-arm Phase 1/2 study; Month 12 data rest on n=3 (DL3) and n=5 (DL4). No randomized comparator exists, background antiepileptic drug use is unspecified, and no precedent with matching mechanism has cleared regulatory or HTA review.
| Indication | Dravet syndrome |
| Drug | ETX101 |
| Mechanism of Action | SCN1A gene expression enhancer |
| Company | Encoded Therapeutics, Inc. |
| Trial Phase | Phase 1/2 |
| Trial Acronym | POLARIS |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Rare Diseases & Genetics |
| Conference Name | 16th European Epilepsy Congress |
| Presenter | Professor Ingrid Scheffer |
| Patient Population | children and adolescents with SCN1A+ Dravet syndrome |
| Dosage Levels | DL3, DL4 |
| Follow-up Duration | up to 117 weeks |
| Primary Efficacy Measure | Monthly Countable Seizure Frequency (MCSF) reduction |
| Cognitive Assessment Tool | Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) |
| Adaptive Behavior Assessment Tool | Vineland Adaptive Behavior Scales, Third Edition (VABS-3) |
| Regulatory Designations | Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track, Rare Pediatric Disease, Orphan Drug (FDA), Orphan (EMA), CMC Development and Readiness Pilot (FDA) |
| Administration Route | single intracerebroventricular (ICV) injection |
ETX101 Gene Therapy Shows Sustained Seizure Reduction and Neurodevelopmental Gains
Encoded Therapeutics announced updated Phase 1/2 POLARIS data for ETX101, an investigational AAV9-based gene regulation therapy for SCN1A+ Dravet syndrome, presented at the 16th European Epilepsy Congress. The data showed substantial and durable reductions in monthly countable seizure frequency (MCSF), with DL3 participants (n=5) achieving a median reduction of approximately 76% and DL4 participants (n=9) achieving approximately 60% through 52 weeks. At Month 12, reductions were 79% for DL3 (n=3) and 89% for DL4 (n=5). Additionally, ETX101 demonstrated progressive gains in cognition and adaptive behavior, particularly in children treated before two years of age, with developmental trajectories approaching neurotypical children. The therapy maintained a favorable safety profile across all dose levels, with no treatment-related serious adverse events.
- ETX101 demonstrated substantial and durable reductions in monthly countable seizure frequency (MCSF) following a single administration. In the cumulative analysis, dose level 3 (DL3; n=5) and DL4 participants (n=9) achieved median MCSF reductions of approximately 76% and 60%, respectively, through 52 weeks. Among participants completing 52 weeks, the median MCSF reduction at Month 12 was approximately 79% for DL3 (n=3) and 89% for DL4 (n=5), highlighting sustained efficacy.
- The presented data showed progressive gains in cognition and adaptive behavior, particularly in participants treated before two years of age. Bayley-4 cognitive growth scale values (GSVs) indicated developmental trajectories approaching those expected for neurotypical children, diverging from natural history. Clinically meaningful improvements were also observed across all Vineland Adaptive Behavior Scales (VABS-3) domains, including communication, motor skills, socialization, and daily living skills, narrowing the gap with neurotypical peers.
- ETX101 exhibited a favorable safety profile and was well-tolerated across all four dose levels with up to 117 weeks of follow-up. No treatment- or procedure-related serious adverse events were reported. Treatment-related adverse events, such as clinically asymptomatic and resolved transaminase elevations (n=7/21) and thrombocytopenia (n=3/21), further support the therapy's safety and tolerability profile.
ETX101's Sustained Seizure Reduction and Neurodevelopmental Gains
Several recent clinical studies have evaluated novel and established interventions for Dravet syndrome, yielding meaningful efficacy and safety data across distinct patient populations.
The GWPCARE5 open-label extension trial examined long-term add-on cannabidiol (CBD) — a pharmaceutical formulation of highly purified CBD in oral solution (100 mg/ml) — in 315 patients who had completed the randomized controlled trials GWPCARE1 Part B and GWPCARE2. Over a median treatment duration of 444 days, with a mean modal dose of 22 mg/kg/day, the median reduction from baseline in monthly convulsive seizure frequency assessed in 12-week periods up to Week 156 ranged from 45% to 74%, and from 49% to 84% for total seizures. Adverse events (AEs) occurred in 97% of patients; commonly reported AEs were diarrhea (43%), pyrexia (39%), decreased appetite (31%), and somnolence (28%). Twenty-eight patients (9%) discontinued due to AEs, and 69 patients (22%) had liver transaminase elevations >3 × upper limit of normal, of whom 84% were on concomitant valproic acid. Across all visit windows, ≥83% of patients/caregivers completing a Subject/Caregiver Global Impression of Change scale reported improvement in overall condition.
A randomized clinical trial evaluating fenfluramine (0.4 mg/kg/d; maximum 17 mg/d) in patients with Dravet syndrome receiving stiripentol-inclusive regimens enrolled 87 patients (mean age 9.1 years) with a mean baseline frequency of approximately 25 convulsive seizures per month. Patients treated with fenfluramine achieved a 54.0% (95% CI, 35.6%–67.2%; P < .001) greater reduction in mean monthly convulsive seizure frequency than those receiving placebo, and 54% of fenfluramine-treated patients demonstrated a clinically meaningful (≥50%) reduction versus 5% with placebo (P < .001). The median longest seizure-free interval was 22 days with fenfluramine versus 13 days with placebo (P = .004). The most common AEs were decreased appetite (44% vs. 11% with placebo), fatigue (26% vs. 5%), diarrhea (23% vs. 7%), and pyrexia (26% vs. 9%). Cardiac monitoring demonstrated no clinical or echocardiographic evidence of valvular heart disease or pulmonary arterial hypertension. This evidence was further supported by a long-term open-label extension study of fenfluramine in 374 patients with Dravet syndrome, including 45 adults, with a median exposure of 824 days. The median percentage change in monthly convulsive seizure frequency from baseline to end of study in the modified intent-to-treat population (n = 324) was -66.8% (p < .001), with no new or unexpected safety signals observed and no valvular heart disease or pulmonary arterial hypertension identified over the extension period.
The Persistent Burden of Dravet Syndrome and Unmet Needs
Despite meaningful advances in understanding Dravet syndrome (DS), substantial unmet needs persist across the disease spectrum — spanning seizure control, neurodevelopmental outcomes, and mortality risk. The literature from the past three years consistently identifies several distinct clinical and molecular gaps that are actively shaping the therapeutic landscape.
Pharmacoresistant seizures and absence of disease-modifying therapy: Current antiseizure medications rarely achieve complete seizure freedom, and DS remains "largely refractory to current antiseizure medications." This has driven the field toward gene-targeted strategies — including antisense oligonucleotides (ASOs) and viral-based therapies — as the first potential disease-modifying interventions.
Progressive neurodevelopmental decline: Registry data from the Italian Residras cohort (281 patients with confirmed SCN1A mutations) documented significant worsening over a 5-year follow-up in cognitive function (P < 0.001), language (P = 0.001), intellectual disability (P < 0.001), and behavioral disorders including attention deficit (P < 0.001). Current treatments fail to prevent this cognitive decline, representing a critical unmet need beyond seizure control.
SUDEP risk and mortality: DS carries a mortality rate of 15 per 1,000 — with SUDEP accounting for approximately two-thirds of cases. The Residras registry recorded a mortality rate of 1.84 per 1,000 person-years in its cohort. Preclinical work with stiripentol has demonstrated dose-dependent prevention of lethal seizures in audiogenic models, but SUDEP prevention remains an active and unresolved clinical priority.
Delayed and missed molecular diagnosis: Delayed molecular diagnosis leads to inappropriate exposure to sodium channel-blocking agents, which aggravate seizures in SCN1A-related DS. Early genetic testing in infants with early-onset seizures is identified as a key gap, with next-generation sequencing and multiplex ligation-dependent probe amplification highlighted as tools to accelerate diagnosis.
Non-coding and deep intronic variant populations: A subset of patients harbor pathogenic deep intronic variants — including those associated with newly identified "poison exons" in introns 1 and 22 of SCN1A — that are missed by standard coding-region sequencing. These patients represent an underdiagnosed population for whom targeted ASO-based splice-modulating therapies are being developed as precision medicine approaches.
Adults with DS: The Residras registry explicitly includes adult patients, and the broader literature calls for management strategies that extend into adulthood — encompassing cognitive preservation, SUDEP prevention, and sleep disorders — areas where evidence and dedicated therapeutic strategies remain limited.
Immunogenic safety and clinical validation of viral gene therapies: While AAV9-mediated SCN1A delivery and CRISPR/dCas9-driven Nav1.1 upregulation have shown preclinical promise, "comprehensive validation will be essential to ascertain their immunogenic safety and demonstrate clinical efficacy," representing a forward-looking unmet need for this therapeutic class.
Designing POLARIS: Targeting Dravet Syndrome's Root Cause
Several pivotal randomized controlled trials have evaluated investigational and approved therapies for Dravet syndrome (DS), each employing distinct design parameters, dosing regimens, and endpoint structures. The table below summarizes the key study design elements and endpoints across these trials.
| Trial / Study | Drug | Population | Design | Duration | Dosing | Primary Endpoint | Key Secondary Endpoints | Key Efficacy Results | Key Safety Findings |
|---|---|---|---|---|---|---|---|---|---|
| SKYLINE (NCT04940624) | Soticlestat | DS patients aged 2–21 years; ≥4 convulsive seizures/month despite adequate treatment | Multicenter, randomized, double-blind, placebo-controlled, phase 3 | 16 weeks (4-week titration + 12-week maintenance) | Oral soticlestat 300 mg (weight adjusted) or matching placebo, twice daily | Comparison of monthly convulsive seizure frequency between baseline and the titration/maintenance periods | Modified Caregiver and Clinical Global Impression of Improvement (GI-I) scales for DS | Median change from baseline in convulsive seizure frequency: -8.64% (placebo) vs. -22.16% (soticlestat); difference of -15.64% (p = .061); ≥50% responder rate: 9.9% (placebo) vs. 27.4% (soticlestat) (nominal p = .008) | Somnolence, change in seizure presentation, decreased appetite, insomnia |
| GWPCARE1 (NCT02091375) & GWPCARE2 (NCT02224703) | Cannabidiol (CBD) | DS patients aged 2–18 years (mean age 9.5 years); median of 3 current antiepileptic drugs | Randomized controlled trials | 14 weeks (14-day titration + maintenance) | CBD 10 mg/kg/day (CBD10; GWPCARE2) or 20 mg/kg/day (CBD20; GWPCARE1&2), or matching placebo; titration started at 2.5 mg/kg/day, reached 10 mg/kg/day on Day 7, up to 20 mg/kg/day on Day 11 | Percentage change from baseline in convulsive seizure frequency (post-hoc: calculated by cumulative day) | 50% responder rate; time to onset and resolution of adverse events | Differences in convulsive seizure reduction between placebo and CBD became nominally significant by Day 12 for CBD20 (p = .02) and Day 13 for CBD10 (p = .03) | Somnolence, decreased appetite, and diarrhea; most resolved within 4 weeks of onset in 56.3%–72.9% of CBD-treated patients |
| GWPCARE 1B & GWPCARE 2 (pooled placebo analysis) | Placebo (cannabidiol trials) | DS patients aged 2–18 years; ≥4 convulsive seizures during 4-week baseline | Exploratory post-hoc analysis of pooled placebo-treated patients from two phase III RCTs | Not reported | Matched placebo | Convulsive seizure frequency; convulsive seizure-free days; Caregiver Global Impression of Change | Safety and quality of life outcomes | Decreased median convulsive seizure frequency during treatment vs. baseline; convulsive seizure-free days similar to baseline; placebo had very little effect on Caregiver Global Impression of Change | Most treatment-emergent adverse events resolved quickly; serious adverse events were infrequent |
| Nabbout et al. / Legae et al. RCTs (fenfluramine) | Fenfluramine (Fintepla) | DS patients | Randomized controlled trials (details not further specified) | Not reported | Not reported | Not reported | Not reported | Success of RCTs led to FDA approval of fenfluramine in 2020 | Cardiac valvulopathy concern not reproducible with low-dose fenfluramine |
| Zogenix Early Access Program (real-world) | Fenfluramine | DS patients; median age 8.6 years (IQR = 4.1–13.9); 52 patients enrolled | Real-world, add-on study at four Italian pediatric epilepsy centers | Median follow-up 9.0 months (IQR = 3.2–9.5) | Add-on, twice daily; initial dose 0.2 mg/kg/d up to 0.7 mg/kg/d | Reduction in convulsive seizures | ≥50% and ≥75% responder rates; seizure-free rate; cardiac safety (Doppler echocardiography every 3–6 months) | 77.4% median reduction in convulsive seizures at last follow-up; 71.1% had ≥50% reduction; 53.3% had ≥75% reduction; 11.1% were seizure-free | Decreased appetite (13.4%); no echocardiographic signs of cardiac valvulopathy or pulmonary hypertension |
| Stiripentol retrospective study | Stiripentol | 131 DS patients (59 females, 72 males) initiating stiripentol before 2 years of age; data from four French longitudinal databases (1991–2021) | 30-year, real-world retrospective study | Short-term (<6 months; median 4 months); long-term (last visit <7 years of age; median stiripentol 28 months) | Added to valproate and clobazam (93%); median dose 50 mg/kg/day at 13 months | Frequency of tonic-clonic seizures (TCS) lasting >5 minutes; status epilepticus (>30 minutes) | Emergency hospitalizations; mortality; adverse events | Short-term: frequency of TCS >5 minutes decreased (p < 0.01); status epilepticus disappeared in 55% of patients. Long-term: frequency of long-lasting TCS continued to decline (p = 0.03); emergency hospitalizations dropped from 91% to 43% (short-term) and 12% (long-term) (p < 0.001) | 55% reported ≥1 adverse event; most common: loss of appetite/weight (21%), somnolence (11%); 3 patients discontinued due to adverse events; 3 deaths (all sudden unexpected death in epilepsy) |
ETX101: A New Horizon for Dravet Syndrome Treatment
Dravet syndrome stands as one of the most challenging developmental and epileptic encephalopathies, characterized by severe, drug-resistant seizures and profound neurodevelopmental impairments. Despite the advent of new antiseizure medications, many patients continue to experience high seizure burden, and critically, the associated cognitive and communication delays often persist, independent of seizure control. Research indicates that developmental stagnation can occur after age two, underscoring a narrow, optimal therapeutic window for interventions aimed at preventing language and communication deficits.
Encoded Therapeutics' updated Phase 1/2 data for ETX101 offers a compelling glimpse into a potential new era for Dravet syndrome management. This AAV9-based gene regulation therapy directly targets the underlying SCN1A gene defect, moving beyond symptomatic relief to address the root cause of the disease. The reported substantial and durable reductions in monthly countable seizure frequency are significant, but perhaps even more impactful are the progressive gains in cognition and adaptive behavior, particularly in very young children. This suggests ETX101 could offer a truly disease-modifying approach, a critical differentiator in a landscape where current treatments primarily focus on seizure reduction.
However, as with any groundbreaking therapy, particularly gene-based interventions, important considerations remain:
Long-term Data: While the current safety profile is favorable and efficacy durable through 52 weeks, comprehensive long-term safety and efficacy data will be crucial to fully understand the sustained benefits and potential late-onset effects of this gene therapy.
Age-Dependent Efficacy: The emphasis on benefits in children treated before two years of age highlights the potential for a narrow therapeutic window for optimal neurodevelopmental outcomes, necessitating early diagnosis and intervention strategies.
Competitive Landscape: The field of precision medicine for Dravet syndrome is advancing rapidly, with other RNA and gene-based therapies in development. Future competition will shape market dynamics and patient access.
Ultimately, these data reinforce the growing momentum towards precision medicine in severe genetic epilepsies. If ETX101 continues to demonstrate these comprehensive benefits in larger trials, it could fundamentally reshape the treatment paradigm, offering not just seizure control, but a path towards improved neurodevelopmental trajectories for children with SCN1A+ Dravet syndrome.
Frequently Asked Questions
References
- [1] Madan Cohen J, Checketts D et al.. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials. Epilepsia. 2021 Sep. 34265088
- [2] Weiss CR, Abiola GO et al.. Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) Trial: Results at 1 Year. Radiology. 2019 Jun. 30938624
- [3] Devinsky O, Hyland K et al.. Placebo response in patients with Dravet syndrome: Post-hoc analysis of two clinical trials. Epilepsy & behavior : E&B. 2024 Jul. 38677101
- [4] Simon K, Sheckley H et al.. A review of fenfluramine for the treatment of Dravet syndrome patients. Current research in pharmacology and drug discovery. 2022. 34988433
- [5] Miziak B, Czuczwar S. Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome. Expert opinion on drug discovery. 2021 May. 33275464
- [6] Scheffer IE, Nabbout R et al.. Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. Epilepsia. 2025 Jun. 40072476
- [7] Griffin AL, Jaishankar P et al.. Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome. Brain communications. 2019. 31667472
- [8] Devinsky O, Nabbout R et al.. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia. 2019 Feb. 30582156
- [9] Silvennoinen K, Ritter LM et al.. Two-center experience of cannabidiol use in adults with Dravet syndrome. Seizure. 2021 Oct. 34052628
- [10] Sullivan J, Valente K et al.. Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome. Epilepsia. 2026 Jun. 41784472
- [11] Guerrero Ruiz GDP. [Sudden unexpected death in epilepsy: risk factors, prevention strategies, and approaches for family engagement]. Medicina. 2025 Sep. 41036978
- [12] Zeng B, Zhang H et al.. Identification of five novel SCN1A variants. Frontiers in behavioral neuroscience. 2023. 38025388
- [13] Tang S, Stamberger H et al.. Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome. JCI insight. 2025 Feb 13. 39946203
- [14] Şengenç E, Şahin ŞS et al.. Molecular Analysis of SCN1A Gene Variants Associated with Dravet Syndrome: Implications for Diagnosis and Management. Turkish archives of pediatrics. 2026 Jul 13. 42541470
- [15] Bacq A, Robert A et al.. Stiripentol prevents lethal audiogenic seizures in two mouse strains, relevant for SUDEP prevention. Epilepsy & behavior : E&B. 2025 Nov. 40472716
- [16] Riva A, Di Gioacchino S et al.. At the forefront of gene-based therapies in Dravet syndrome. Expert opinion on emerging drugs. 2026 Sep. 42268240
- [17] Liu YH, Kuo CY et al.. Dravet Syndrome: Past, Present, and Future. Acta neurologica Taiwanica. 2025 Jul 1. 41020456
- [18] Scheffer IE, Halford JJ et al.. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021 Oct. 34406656
- [19] Specchio N, Pietrafusa N et al.. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study. Epilepsia. 2020 Nov. 32945537
- [20] Chiron C, Chemaly N et al.. Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus. Developmental medicine and child neurology. 2023 Dec. 37198755
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
